HOOKIPA Pharma Receives FDA Clearance of its IND Application for HB-700 for the Treatment of KRAS-Mutated Cancers
DENVER, Colo., Apr 24, 2024 (247marketnews.com)- HOOKIPA Pharma Inc. (NASDAQ:HOOK) received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-700, for the treatment of KRAS-mutated cancers, triggering a final $10 million milestone payment from Roche.
“We are proud to have another IND cleared for a potentially powerful oncology program. Our HB-700 program targets five KRAS-mutations found in multiple cancer indications with a single product candidate,” commented Joern Aldag, Chief Executive Officer at HOOKIPA. “Importantly, the submission of the IND results in us receiving a final $10 million milestone payment. We continue to define our clinical development strategy which includes the possibility of collaboration or partnership for this program.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (HOOK)
- MoBot’s Stock Market Highlights – 05/01/25 03:00 PM
- HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
- 24/7 Market News Snapshot 10 January, 2025 – HOOKIPA Pharma Inc. Common Stock (NASDAQ:HOOK)
- Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
- Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA